We prospectively analyzed the safety of the perioperative use of low molecular weight heparin (LMWH) for prophylaxis of thromboembolic complications after radical retropubic prostatectomy (RRP).
Introduction
Thromboembolic complications remain the most common cause of major morbidity and mortality after radical prostatectomy. Clinically recognized deep venous thrombosis (DVT) is reported in up to ®ve percent of patients after radical retropubic prostatectomy and pulmonary embolus (PE) occurs in one to three percent. Although mortality is observed in fewer than one percent of patients, 1 PE is the most common cause of death in most large series of patients undergoing radical prostatectomy.
Several methods for the prophylaxis of thromboembolic events after radical prostatectomy have been used with variable success. Most commonly, calf compression either with elastic thromboembolic stockings or intermittent pneumatic sequential compression devices (SCD) has been used. However, the ef®cacy of these methods in patients undergoing radical prostatectomy has not been established and one report suggested this approach was not effective in this patient population. 1 Anticoagulant therapy with either orally administered anticoagulants such as warfarin or perioperative administration of heparin have been demonstrated in multiple reports to be the most effective means of DVT prophylaxis for many surgical procedures. 2 These methods have not found much acceptance with radical prostatectomy because of concerns about excessive bleeding or increased lymphatic drainage and lymphocele formation.
Low molecular weight heparin (LMWH) has several apparent advantages compared with unfractionated heparin. Less frequent dosing is required because of a longer serum half life. Moreover, some studies have shown less risk of thrombocytopenia and bleeding complications with LMWH compared with unfractionated heparin. 3, 4 We report the results of a prospective study designed to address the safety of LMWH used in patients undergoing radical retropubic prostatectomy.
Materials and methods
All patients who have undergone radical retropubic prostatectomy at our institution since July 1993 have been managed on a highly standardized care pathway. 5, 6 This program standardizes all aspects of the care of these patients including pre-operative preparation, transfusion practices, method of anesthesia, and post-operative care many of which could possibly affect the incidence of DVTs. Clinical management is carefully tracked and clinical outcomes 30 d after surgery are recorded by a clinical nurse manager after review of the clinical record and patient interview. In February 1995, we initiated a prospective trial through our care pathway and began the use of LMWH (Enoxaparin) for DVT prophylaxis. Thirty milligrams of LMWH were administered subcutaneously one hour prior to the surgical procedure and continued at that dose every twelve hours until discharge from the hospital.
We analyzed prospectively the outcomes in 73 consecutive patients who received perioperative LMWH with radical retropubic prostatectomy and made comparisons with a matched group of patients undergoing radical retropubic prostatectomy using elastic stockings only for DVT prophylaxis immediately prior to this study. All patients underwent radical prostatectomy by one of the authors and a single closed suction drain routinely was placed in the pelvis at the end of the surgical procedure. Drains were removed when output was less than 50 cc in a 24 h period. Values for surgical time and estimated blood loss were taken from the anesthesia record. A hematocrit was obtained at the time of the pre-anesthesia screening visit and on the morning of post-operative day number one. Pathology specimens were analyzed using a whole mount technique. The patients treated with LMWH were compared to a group of 89 consecutive patients treated immediately before the initiation of this study. None received heparin prophylaxis and none had pneumatic compression devices. Elastic stockings and early ambulation were the only method of DVT prophylaxis. Statistical comparisons were made by non-paired student's t-test or by two-tailed chi-square analysis where appropriate. P values of less than 0.05 were considered statistically signi®cant. Table 1 shows comparative features for overall surgical parameters. The groups were comparable with respect to surgical time, hospital stay, and the incidence of positive margins. A greater percentage of the elastic stocking group underwent simultaneous pelvic lymph node dissection at the time of radical prostatectomy P `0.001). Virtually all patients in both groups had general endotracheal anesthesia. All patients in both groups received parenteral ketorolac to supplement narcotic analgesia in the ®rst 48 h post-operatively. A mean of seven doses of enoxaparin were administered to the LMWH group.
Results
Estimated blood loss, transfusion requirements, and uid replacement were similar in the two groups of patients (Table 2) . Pre-and post-operative hematocrit levels were identical in the two groups, suggesting that the indication for transfusion of blood products was the same in both patient populations. There was a slightly greater utilization of autologous blood products in the patients who were treated with elastic stockings. This re¯ects our decreased utilization of autologous blood predeposit over time rather than a bene®cial effect of LMWH. The pertinent observation is that intra-operative blood loss and transfusion requirement were not increased as a consequence of the peri-operative use of LMWH. The percentage of patients receiving any form of blood transfusion was lower in the LMWH group (P 0.004).
Closed suction drainage output is listed in Table 3 . The use of LMWH did not appear to increase drainage nor the length of time for which drains remained in place. A single patient in the LMWH group (1.3%) had drainage of greater than 100 cc on post-operative day number four and was sent home with the drain indwelling. No patient in the elastic stocking group had drainage exceeding 100 cc per day by post-operative day number four and none were discharged with the drain indwelling. Complications in the two groups are listed in Table 4 . Infectious complications, either febrile urinary tract infections or wound infections, were the most common problem seen in both groups. A total of 3.3% of the patients with elastic thromboembolism stockings suffered some form of thromboembolic event and no patient in the LMWH group experienced a documented thromboembolic complication (P 0.026). However, a single patient in the LMWH group presented to the emergency department 13 d post-operatively complaining of back pain and abdominal discomfort, possibly from a ruptured aortic aneurysm. He suffered a complete cardiopulmonary arrest and could not be resuscitated. A post-mortem examination was not granted.
A total of 7% of patients experienced a complication which was probably directly attributable to the LMWH. Two patients had minimal intra-operative blood loss but experienced a precipitous drop in their serum hematocrit by the following morning. One required transfusion of 4 units of allogeneic blood and the other remained stable with a hematocrit of 18% after LMWH was discontinued. This same patient required readmission ten days postoperatively for percutaneous drainage of an infected pelvic hematoma. Two patients developed a signi®cant scrotal or wound hematoma; one of these had a penile implant performed simultaneously with the prostatectomy. A ®nal patient developed left thigh and abdominal pain three weeks post-operatively and required percutaneous drainage of an infected pelvic lymphocele. Six percent of patients had LMWH discontinued by the attending surgeon either immediately after surgery or in the ®rst 24 h because of a concern regarding ongoing pelvic bleeding or hematuria.
Discussion
Venous stasis during surgery, the vasodilatory effects of anesthesia, and the hypercoagulable state which occurs postoperatively all contribute to the risk of thromboembolic events after abdominal and pelvic surgery. 7 Fibrinogen labeled uptake tests indicate the presence of calf DVT in up to 25% of patients undergoing radical retropubic prostatectomy. 2 Most of these represent super®cial calf or leg vein thromboses which are not clinically relevant. Clinically recognized and symptomatic DVT is less common but still accounts for prolonged hospitalization or readmission in three to ®ve percent of patients undergoing radical prostatectomy without anticoagulant prophylaxis, an incidence similar to what we found in our elastic stocking group. Pulmonary embolus is observed in only one to two percent of patients after radical prostatectomy with a fatal outcome in fewer than one percent of patients. However, this still constitutes one of the most frequent causes of mortality after radical prostatectomy.
Calf compression devices frequently are used for prophylaxis of DVT based upon the premise that active or intermittent milking of the deep veins of the calf helps prevent venous stasis. 8 The safety and ef®cacy of intermittent pneumatic compression devices after radical prostatectomy has been studied in several retrospective series. Strup et al 9 found a statistically signi®cant increase in blood loss in patients using SCDs during radical prostatectomy compared with those who did not. Other series have not supported these ®ndings. 10 Regardless of their effect on blood loss, SCDs have no proven bene®t in patients undergoing radical prostatectomy. The marginal effectiveness of these devices probably is explained by the fact that venous stasis is only one component of the cascade of events which leads to thromboembolic complications after surgery.
In contrast, the effectiveness of anticoagulants in preventing thromboembolic events after multiple types of operations, however, is well-established. 2 Oral warfarin or subcutaneous heparin have been used most commonly and have consistently been shown to decrease the incidence of both radiologically detected and clinically signi®cant DVT and PE compared with no anticoagulant prophylaxis. 8 Concerns about increased bleeding have, however, limited the use of anticoagulant prophylaxis. Nevertheless, a large number of prospective studies have shown a minimal increase in hemorrhagic complications in patients receiving anticoagulant prophylaxis although there has been a small increase in the incidence of wound or operative site hematoma. Another issue with anticoagulant use has been the possibility of an increase in lymphatic drainage after lymph node dissection. Catalona, et al reported an increased risk of lymphoceles in patients who received heparin before radical retropubic prostatectomy and lymph node dissection. 11 This study reported that in eight patients that underwent radical prostatectomy while receiving standard heparin prophylaxis, lymphoceles andaor prolonged lymphatic drainage occurred in 38% of patients. Despite the fact that these conclusions have not been validated in series with greater numbers of patients, the development of lymphoceles after radical prostatectomy in patients treated with heparin has been cited as a reason not to use this form of DVT prophylaxis in this population.
A question of importance is the timing and duration of anticoagulant prophylaxis. Previous concepts that the inciting event for DVT occurs on the operating table probably are too simplistic. Over half of clinically recognized PEs occur after hospital discharge and more than seven days postoperatively. 12 Studies evaluating anticoagulant prophylaxis started postoperatively show little apparent compromise in ef®cacy compared with those when prophylaxis was initiated before surgery 13 We chose to administer the LMWH immediately pre-operatively and to continue it throughout the patient's hospital stay.
LMWH has some theoretical and practical advantages compared with unfractionated heparin. The longer half life allows less frequent administration. Animal studies show less risk of hemorrhagic complications with LMWH.
14 In addition, LMWH has little effect on protime (PT) or partial thromboplastin time (PTT), eliminating the need for monitoring of these parameters. Clinical studies have not consistently shown a more favorable safety pro®le for LMWH compared with unfractionated heparin in patients considered at moderate risk for thromboembolic complications. 15 The main argument against the use of these compounds are that LMWH compounds are more expensive than unfractionated heparin.
Our study was not intended to test the ef®cacy of LMWH prophylaxis of thromboembolic events as only a large randomized prospective trial would have suf®cient power to detect the small differences which may occur. Rather, we conducted this study to examine the safety of LMWH in a radical prostatectomy patient population and speci®cally to evaluate the incidence of complications from lymphatic drainage or bleeding. Previous studies have included smaller numbers of patients or have not carefully evaluated the risks and side effects of anticoagulants used with radical prostatectomy. Intraoperative blood loss was not in¯uenced by the use of LMWH. Median estimated blood loss was 515 ml in the group of patients receiving LMWH preoperatively. There was no measurable increase in the quantity of drain output and the drain was removed from all but one patient by the third postoperative day.
Some complications were, however, probably attributable to the use of LMWH. Two patients had clot retention postoperatively and there was a general impression of more blood in the urine and for a longer duration than typically seen after radical retropubic prostatectomy without the use of anticoagulants. One patient developed a lymphocele which required drainage. The pelvic hematoma and the scrotal hematoma seen in two patients postoperatively were problems we had not observed prior to the use of LMWH. While it is possible that LMWH might have had a better safety pro®le if we had not used ketorolac for analgesia, the elastic stocking group also received ketorolac. 16 Nonetheless, the combination of LMWH and ketorolac could have contributed to some of the complications we observed.
These data are important in that they demonstrate that LMWH can be used safely in conjunction with radical prostatectomy. Since anticoagulants have demonstrated effectiveness in preventing perioperative thromboembolic complications, their use should be considered in high risk patients undergoing radical prostatectomy such as obese men or those with a prior history of DVT. However, a certain number of patients will have complications attributable to anticoagulation so we have chosen to not use LMWH routinely with radical prostatectomy.
